Patients with moderate to severe chronic spontaneous urticaria that were antihistamine-resistant to omalizumab experienced ...

Jason Hawkes, MD, MS, provided an in-depth look at the potential role of dupilumab (Dupixent; Sanofi and Regeneron ...

Vets are already seeing a return of snake bites to pets as the weather continues to warm in Northern Colorado.

The regulatory decision announced Friday covers the treatment of patients age 12 and older whose chronic spontaneous urticaria (CSU) symptoms continue despite treatment with standard-of-care ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

If you’re one of the 21% of American adults living with arthritis, you may have searched the web or social media to find out ...

“This FDA approval provides a new treatment option to help address the underlying drivers of these severe and recurring signs and symptoms. Dupixent has the potential to improve outcomes for CSU ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent has experienced few setbacks. One came in 2023, however, when the FDA ...

which plays a key role in CSU symptoms. Dupixent is available as a prefilled pen for shots under the skin and is used with standard antihistamines. After the first dose, it's given every two weeks ...

The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new targeted drug for the inflammatory skin disease in over a decade ...

CHRONIC spontaneous urticaria (CSU) is a distressing inflammatory skin condition characterised by the recurrent appearance of ...

As the Grand Valley’s population grows and its farming community shrinks, agricultural burning becomes a more contentious ...